PMID- 18261810
OWN - NLM
STAT- MEDLINE
DCOM- 20080701
LR  - 20140325
IS  - 0166-4328 (Print)
IS  - 0166-4328 (Linking)
VI  - 189
IP  - 1
DP  - 2008 May 16
TI  - Sub-chronic nandrolone treatment modifies neurochemical and behavioral effects of 
      amphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in rats.
PG  - 191-201
LID - 10.1016/j.bbr.2007.12.021 [doi]
AB  - Misuse of anabolic-androgenic steroids (AASs) is increasing, and appears to have 
      much in common with the use of substances known to induce drug dependence. 
      Moreover, persons who abuse AASs also tend to abuse other psychotropic drugs such 
      as amphetamine or 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). The aim of 
      this study was to investigate whether nandrolone (5 x 5 or 5 x 20 mg/kg) 
      pre-exposure modulates the acute neurochemical and behavioral effects of 
      amphetamine (1mg/kg) and MDMA (5 mg/kg) in rats. Dopamine (DA), 
      5-hydroxytryptamine (5-HT) and their metabolites were measured from samples 
      collected from the nucleus accumbens (NAc) by in vivo microdialysis. The behavior 
      of the animals was recorded on videotapes, from which it was later rated. Our 
      results demonstrate that sub-chronic treatments with supraphysiological doses of 
      nandrolone attenuate dose-dependently the increase in extracellular DA 
      concentration evoked by amphetamine or MDMA. The lower dose of nandrolone 
      attenuated MDMA-induced increase in 5-HT-levels, while the higher dose 
      potentiated it. Analysis of the behavioral data suggests that effects of the 
      amphetamine and MDMA are dose-dependently attenuated by AAS-treatment, 
      paralleling DA results. In conclusion, the results of this study show that 
      AAS-pre-treatment is able to modulate the reward-related neurochemical and 
      behavioral effects of amphetamine and MDMA.
FAU - Kurling, Sanna
AU  - Kurling S
AD  - Drug Research Unit, Department of Mental Health and Alcohol Research, National 
      Public Health Institute, Helsinki, Finland. sanna.kurling@ktl.fi
FAU - Kankaanpaa, Aino
AU  - Kankaanpaa A
FAU - Seppala, Timo
AU  - Seppala T
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080105
PL  - Netherlands
TA  - Behav Brain Res
JT  - Behavioural brain research
JID - 8004872
RN  - 0 (Adrenergic Uptake Inhibitors)
RN  - 0 (Anabolic Agents)
RN  - 333DO1RDJY (Serotonin)
RN  - 6PG9VR430D (Nandrolone)
RN  - CK833KGX7E (Amphetamine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Adrenergic Uptake Inhibitors/*pharmacology
MH  - Amphetamine/*pharmacology
MH  - Anabolic Agents/*administration & dosage
MH  - Analysis of Variance
MH  - Animals
MH  - Area Under Curve
MH  - Behavior, Animal/*drug effects
MH  - Dopamine/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug Interactions
MH  - Male
MH  - Microdialysis
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Nandrolone/*administration & dosage
MH  - Nucleus Accumbens/drug effects/metabolism
MH  - Rats
MH  - Rats, Wistar
MH  - Reward
MH  - Serotonin/metabolism
MH  - Statistics, Nonparametric
EDAT- 2008/02/12 09:00
MHDA- 2008/07/02 09:00
CRDT- 2008/02/12 09:00
PHST- 2007/06/26 00:00 [received]
PHST- 2007/12/28 00:00 [accepted]
PHST- 2008/02/12 09:00 [pubmed]
PHST- 2008/07/02 09:00 [medline]
PHST- 2008/02/12 09:00 [entrez]
AID - S0166-4328(08)00003-X [pii]
AID - 10.1016/j.bbr.2007.12.021 [doi]
PST - ppublish
SO  - Behav Brain Res. 2008 May 16;189(1):191-201. doi: 10.1016/j.bbr.2007.12.021. Epub 
      2008 Jan 5.